# About BPC-157 Telehealth — Editorial Standards and Publisher Entity > About BPC-157 Telehealth: an independent editorial publisher summarizing the peer-reviewed research literature on Body Protection Compound 157. Editorial standards, sourcing methodology, and disclaimer. BPC-157 Telehealth is an independent editorial project. What it is and is not are stated plainly below. ## Publisher entity BPC-157 Telehealth is an independent editorial project that publishes summaries of the peer-reviewed research literature on Body Protection Compound 157 (pentadecapeptide BPC 157). It is not a clinic. It does not employ clinicians and does not provide medical advice. It does not manufacture, sell, or distribute any product. Its work is editorial commentary on publicly available science. The site name incorporates the term 'telehealth' as editorial framing — a reference to the regulatory and research-infrastructure context in which BPC-157's status is actively debated: FDA Category 2 compounding prohibition, WADA S0 classification, IRB-supervised research protocols, and the distinction between a clinical prescription and a research protocol administered under institutional oversight. This is a domain of active regulatory and scientific discussion. The site documents that discussion. It does not occupy any position in it as a provider, broker, or referral service. No person affiliated with this site is a clinician. No person affiliated with this site is identified as a real individual on any page of this site. No physical address, phone number, or clinic location is associated with this site. No consultation, treatment, or prescription service is offered or implied. ## Editorial standards and sourcing methodology All factual claims on this site are sourced to peer-reviewed publications indexed in PubMed, PMC, ClinicalTrials.gov, or equivalent primary sources. DOI and PMID identifiers are provided for each citation. Citations are numbered in sequence across the site; the same number always references the same source. The site covers the published BPC-157 research record as it exists. Where the evidence base is small (three published human pilot studies, combined n=30), that limitation is stated explicitly. Where the dominant publication source is a single research group (Sikiric et al., University of Zagreb), that concentration is noted. Where key data is missing — unpublished Phase 2 results, cancelled Phase 1 registration, no randomized controlled trials — those gaps are documented rather than papered over. Quantitative claims (dose values, half-life estimates, study counts, effect sizes, p-values) are sourced to specific studies. Every cited figure is traceable to a publication in the references index. No figures are synthesized, averaged across studies without acknowledgment, or presented without a source. **Regulatory framing.** The regulatory section of every page accurately reflects BPC-157's standing as of the site's publication date (2026): FDA Category 2 (Category 2 bulk drug substances list, effective 2023-09-29), WADA S0 (effective 2022), no active IND, no FDA-approved indication, no approved compounding pathway. The FDA Pharmacy Compounding Advisory Committee is scheduled to reconsider BPC-157 acetate and BPC-157 free base for the 503A Bulks List at its July 2026 meeting; this development is noted on relevant pages. If that meeting produces new classification decisions, the site will update accordingly. **Editorial frame.** This site is an independent editorial digest of the peer-reviewed BPC-157 literature, organized by mechanistic pathway. It is not a clinic, not a prescribing service, and not affiliated with any manufacturer or vendor. Nothing on this site constitutes medical advice. ## Regulatory timeline The following chronology documents the key regulatory events in the BPC-157 record: - **Pre-2016:** BPC-157 (as PL14736) completes a Phase 2 trial for ulcerative colitis in Croatia; results never published in a peer-reviewed journal. - **2016:** ClinicalTrials.gov registration NCT02637284 (Phase 1, 42 healthy volunteers) is listed as cancelled; no results published. - **2022:** WADA places BPC-157 on the Prohibited List under S0 — Non-Approved Substances. - **September 2023:** FDA places BPC-157 on the Category 2 bulk drug substances list, prohibiting compounding at 503A pharmacies and 503B outsourcing facilities. - **2024:** Lee, Walker & Ayadi publish intravesicular pilot study (n=12) in Alternative Therapies in Health and Medicine. - **2025:** Lee & Burgess publish IV pharmacokinetic safety pilot (n=2) in Alternative Therapies in Health and Medicine. McGuire et al. (University of Utah) publish a narrative systematic review in Current Reviews in Musculoskeletal Medicine, concluding that clinical use is not supported by current evidence. Sikiric et al. publish comprehensive 2025 review of BPC-157 NO-system and angiogenesis data in Pharmaceuticals (Basel). - **July 2026:** FDA Pharmacy Compounding Advisory Committee meeting scheduled to reconsider BPC-157 acetate and BPC-157 free base for the 503A Bulks List. --- An independent editorial record of the peer-reviewed literature — not a clinic, not a prescribing service.